Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | IDH1 | O75874 | 7/20 | 0.40 |
| ▸ | IDH2 | P48735 | 6/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.36 |
| ▸ | GAA | P10253 | 4/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.33 |
| ▸ | HTR3B | O95264 | 1/20 | 0.33 |
| ▸ | HTR3A | P46098 | 1/20 | 0.33 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.33 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL179546 | 0.79 | L3MBTL1 (0.46) | L3MBTL1IDH1IDH2ALDH1A1GAA | |
| SCHEMBL16419621 | 0.77 | L3MBTL1 (0.44) | L3MBTL1IDH1IDH2ALDH1A1GAA | |
| SCHEMBL1195882 | 0.76 | NOS3 (0.43) | L3MBTL1IDH1ALDH1A1SMN1; SMN2 | |
| SCHEMBL17683928 | 0.75 | L3MBTL1 (0.49) | L3MBTL1IDH1IDH2ALDH1A1GAA | |
| SCHEMBL24774178 | 0.75 | L3MBTL1 (0.43) | L3MBTL1IDH1IDH2ALDH1A1GAA | |
| SCHEMBL12891555 | 0.75 | L3MBTL1 (0.43) | L3MBTL1IDH1IDH2ALDH1A1GAA | |
| SCHEMBL29793734 | 0.75 | L3MBTL1 (0.43) | L3MBTL1IDH1IDH2ALDH1A1GAA | |
| SCHEMBL1645018 | 0.75 | L3MBTL1 (0.43) | L3MBTL1IDH1IDH2ALDH1A1GAA | |
| SCHEMBL21438046 | 0.75 | L3MBTL1 (0.43) | L3MBTL1IDH1IDH2ALDH1A1GAA | |
| SCHEMBL29931101 | 0.75 | L3MBTL1 (0.43) | L3MBTL1IDH1IDH2ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160130278-A1 | GLYCINE TRANSPORTER INHIBITOR | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2016-05-12 | — | — | US | disclosed |
| US-20110166132-A1 | Gamma Secretase Modulators | AMGEN INC. (US) | 2011-07-07 | — | — | US | disclosed |
| EP-2231602-A1 | GAMMA SECRETASE MODULATORS | Amgen, Inc (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009075874-A1 | GAMMA SECRETASE MODULATORS | AMGEN INC. (US) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166132-A1 | Gamma Secretase Modulators | BACE1, BACE2, PSEN1 | L3MBTL1 3332/4885IDH1 2230/4885IDH2 2489/4885 |
| US-20160130278-A1 | GLYCINE TRANSPORTER INHIBITOR | SLC1A2, SLC6A5, SLC18A2 | L3MBTL1 2008/4885IDH1 1811/4885IDH2 2055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.